Business Context and Reporting Period
This Form 8-K is a current report filed by AntriaBio, Inc. (not Rezolute, Inc.) on May 1, 2014. The filing addresses a one-for-six reverse stock split and provides an update on share count following recent equity financings and convertible note conversions completed as of March 31, 2014.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data disclosed relates to capital structure and share counts:
- Pre-Split Share Count (as of March 31, 2014): 102,940,314 shares (increased from 40,000,000 due to recent financings).
- Post-Split Share Count (as of May 1, 2014): 17,156,719 shares.
- Reverse Split Ratio: 1-for-6.
Material Changes
The most significant material change is the reduction in the number of outstanding common shares resulting from the reverse stock split. Additionally, the company notes a substantial increase in share count prior to the split, rising from 40,000,000 to over 102 million shares due to a series of equity financings and the conversion of outstanding convertible promissory notes.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The document is strictly a disclosure of the reverse stock split effectiveness and the resulting share count adjustment. The information is furnished under Regulation FD and is not deemed "filed" for purposes of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the exact date the reverse stock split became effective (stated as May 1, 2014).
- Confirm the adjusted share count of 17,156,719 shares for post-split trading.
- Review the attached press release (Exhibit 99.1) for details on the rationale for the reverse split.
- Check subsequent filings for financial performance data, as this 8-K contains no revenue or earnings figures.